Literature DB >> 12035945

Effects of long-term enalapril and losartan therapy of heart failure on cardiovascular aldosterone.

J C Xiu1, P Wu, J P Xu, Z Guo, W Lai, Y Zhang, S Li, J Li, Y Liu.   

Abstract

Plasma aldosterone escape is found during long-term ACE inhibitor therapy of chronic heart failure. Evidence for aldosterone production in cardiovascular tissues raised the question of whether aldosterone escape occurs or not in these tissues. Rats with infarction-induced chronic heart failure were treated with enalapril (20 mg/kg/d) and losartan (15 mg/kg/d) for 20 weeks. Untreated chronic heart failure and sham-operated rats were used as positive and normal controls, respectively. Ex vivo mesenteric artery and heart perfusion, high performance liquid chromatography, and RIA for aldosterone were performed. Chronic heart failure due to myocardial infarction was associated with tissue-specific activation of cardiovascular aldosterone synthesis. In the mesenteric artery, enalapril significantly inhibited aldosterone production compared to untreated, chronic heart failure rats, and losartan lowered aldosterone production to that of sham rats. In myocardium, enalapril failed to significantly inhibit aldosterone production, and losartan significantly inhibited aldosterone production compared to untreated, chronic heart failure rats. These results provide the first evidence that long-term ACE inhibition therapy induces aldosterone escape in myocardium but not in mesenteric artery of chronic heart failure. The angiotensin II subtype 1 receptor blocker losartan tranquilized aldosterone levels in the cardiovascular tissues of chronic heart failure rats.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12035945     DOI: 10.1007/BF03344039

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  29 in total

1.  Effects of losartan and captopril on left ventricular volumes in elderly patients with heart failure: results of the ELITE ventricular function substudy.

Authors:  M A Konstam; R D Patten; I Thomas; T Ramahi; K La Bresh; S Goldman; W Lewis; A Gradman; K S Self; V Bittner; W Rand; D Kinan; J J Smith; T Ford; R Segal; J E Udelson
Journal:  Am Heart J       Date:  2000-06       Impact factor: 4.749

Review 2.  The cardiac renin-angiotensin system: conceptual, or a regulator of cardiac function?

Authors:  D E Dostal; K M Baker
Journal:  Circ Res       Date:  1999-10-01       Impact factor: 17.367

3.  [The antihypertensive activity of benazepril in the long-term treatment of hypertension patients and its effect on adrenal cortical function].

Authors:  L I Ol'binskaia; S A Golubev; T D Bol'shakova; G V Anastas'ina; A F Buniatian; A A Nosova
Journal:  Ter Arkh       Date:  1995       Impact factor: 0.467

4.  Myocardial production of aldosterone and corticosterone in the rat. Physiological regulation.

Authors:  J S Silvestre; V Robert; C Heymes; B Aupetit-Faisant; C Mouas; J M Moalic; B Swynghedauw; C Delcayre
Journal:  J Biol Chem       Date:  1998-02-27       Impact factor: 5.157

5.  Cardiovascular effects of combination of perindopril, candesartan, and amlodipine in hypertensive rats.

Authors:  S Kim; Y Zhan; Y Izumi; H Iwao
Journal:  Hypertension       Date:  2000-03       Impact factor: 10.190

6.  The effects of angiotensin II receptor blockade with losartan on systemic blood pressure and renal and extrarenal prostaglandin synthesis in women with essential hypertension.

Authors:  M C Smith; S Barrows; A Meibohm; S Shahinfar; R L Simpson; K Weigel; M J Dunn
Journal:  Am J Hypertens       Date:  1995-12       Impact factor: 2.689

7.  An improved perfusion apparatus for small animal hearts.

Authors:  M J Curtis; B A Macleod; R Tabrizchi; M J Walker
Journal:  J Pharmacol Methods       Date:  1986-02

8.  Evidence of a partial escape of renin-angiotensin-aldosterone blockade in patients with acute myocardial infarction treated with ACE inhibitors.

Authors:  C Borghi; S Boschi; E Ambrosioni; G Melandri; A Branzi; B Magnani
Journal:  J Clin Pharmacol       Date:  1993-01       Impact factor: 3.126

Review 9.  Aldosterone escape during angiotensin-converting enzyme inhibitor therapy in chronic heart failure.

Authors:  A D Struthers
Journal:  J Card Fail       Date:  1996-03       Impact factor: 5.712

10.  Aldosterone biosynthesis and action in vascular cells.

Authors:  R Takeda; H Hatakeyama; Y Takeda; K Iki; I Miyamori; W P Sheng; H Yamamoto; I A Blair
Journal:  Steroids       Date:  1995-01       Impact factor: 2.668

View more
  3 in total

Review 1.  RAAS escape: a real clinical entity that may be important in the progression of cardiovascular and renal disease.

Authors:  Jay Lakkis; Wei X Lu; Matthew R Weir
Journal:  Curr Hypertens Rep       Date:  2003-10       Impact factor: 5.369

2.  Cardiac hypertrophy and fibrosis in the metabolic syndrome: a role for aldosterone and the mineralocorticoid receptor.

Authors:  Eric E Essick; Flora Sam
Journal:  Int J Hypertens       Date:  2011-05-22       Impact factor: 2.420

3.  LCZ696 Therapy Reduces Ventricular Tachyarrhythmia Inducibility in a Myocardial Infarction-Induced Heart Failure Rat Model.

Authors:  Po-Cheng Chang; Shien-Fong Lin; Yen Chu; Hung-Ta Wo; Hui-Ling Lee; Yu-Chang Huang; Ming-Shien Wen; Chung-Chuan Chou
Journal:  Cardiovasc Ther       Date:  2019-07-01       Impact factor: 3.023

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.